Quince Therapeutics Inc., a biotechnology company focused on treating rare diseases, has announced a private placement of securities expected to generate approximately $11.5 million in upfront proceeds. The financing, led by Nantahala Capital and involving existing stockholders like ADAR1 Capital Management and Quince's senior management, could potentially raise an additional $10.4 million if the accompanying warrants are fully exercised. Priced at a premium to the last close, the funds are intended for working capital, general corporate purposes, and to support the ongoing Phase 3 NEAT clinical trial in Ataxia-Telangiectasia. Combined with existing resources, this financing is expected to support Quince's operations until mid-2026 or beyond, depending on warrant exercise.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.